Skip directly to site content Skip directly to search


Español  Other Languages


Centers for Disease Control and Prevention. CDC twenty four seven. Saving Lives, Protecting People
 Search

		Submit


Tuberculosis (TB)








Reported Tuberculosis in the United States, 2022						Print
																Related Pages
										Return to Main Menu
Appendix C****
Genotyping Background Information and Glossary
Tuberculosis (TB) genotyping methods are laboratory-based analyses of the genetic material of the bacteria in the *Mycobacterium tuberculosis* complex that cause TB disease. The total genetic content is referred to as the genome. Specific sections of the genome contain distinct genetic patterns that help distinguish different strains of *Mycobacterium tuberculosis*. Conventional TB genotyping examines the location, number, and presence of different types of spacer or repetitive DNA patterns. The areas of the genome examined in TB genotyping are different from those related to drug resistance. Whole-genome sequencing (WGS)-based TB genotyping examines 70%–90% of the genetic sequence of the bacterial genome.
Applications of Genotyping
Patients with TB disease who are related by recent TB transmission should generally have matching genotype results. Conversely, patients with matching TB genotyping results are probably related by transmission in some way, although the connection might not be recent or direct.
Genotyping results, when combined with epidemiologic data, can help identify persons with TB disease involved in the same chain of transmission. This information adds value to TB control activities in different ways. These applications are summarized as follows:
Patient-Level Applications of Genotyping
Support Contact Investigations
Connections identified between ≥2 patients with TB (i.e., epidemiologic linkages) that might or might not be otherwise identified through routine contact investigations can be confirmed or refuted using available genotyping results.
Cluster Investigations
Connections that were not established through routine contact investigations might be suggested by genotyping results and should be investigated further.
Other Applications
Other patient-level applications include detecting and investigating potential false-positive culture results and distinguishing relapse TB disease from new TB infection (i.e., reinfection) among TB patients with recurrent TB disease.
Population-Level Applications of Genotyping
Outbreak detection, assessment, and monitoring
Identify genotype clusters that could represent an outbreak using geospatial or other analyses.
Assess the genetic relatedness of isolates among cases believed to be part of an outbreak.
Define the scope of potential outbreaks by identifying all presumed cases in an area with a matching genotype.
Prospectively monitor known outbreaks for new cases with the same outbreak-related genotype.History of TB Genotyping Surveillance in the United States
In 1996, the Centers for Disease Control and Prevention (CDC) started the National Tuberculosis Genotyping Surveillance Network (NTGSN), a 5-year initiative that established the utility of genotyping in TB control efforts.1 In 2004, based on the knowledge gained from NTGSN and associated studies,2 CDC established the National Tuberculosis Genotyping Service (NTGS) and funded national genotyping laboratories to genotype ≥1 *Mycobacterium tuberculosis* isolate from each culture-positive TB case reported in the United States. All U.S. TB control programs can use NTGS at no cost to patients, health care providers, or health departments. NTGS participation is voluntary, with each program determining how genotyping data will be used for its TB control activities. Since 2004, approximately 170,000 *Mycobacterium tuberculosis* isolates have been successfully genotyped through NTGS and its partnerships among CDC programs, national genotyping laboratories, and state and local jurisdictions.
In 2010, CDC launched the Tuberculosis Genotyping Information Management System (TB GIMS),4 a secure web-based database available to reporting areas in all 50 U.S. states, the District of Columbia, Puerto Rico, the U.S. Virgin Islands, and the U.S.-affiliated Pacific Islands. TB GIMS makes genotyping data easily available to users and facilitates linking of genotyping data to patient surveillance records from the National TB Surveillance System. Key features include database queries of genotypes and clusters, data quality checks, aggregate reports, and outbreak detection tools. As of July 2023, TB GIMS has 615 users among state, tribal, local, territorial, and federal partners.
In 2018, CDC established the National Tuberculosis Molecular Surveillance Center (NTMSC) to perform whole-genome sequencing (WGS) on ≥1 isolate from every culture-positive TB case in the United States. In July 2022, NTMSC fully transitioned from conventional genotyping (e.g., GENType) to WGS and the resulting whole-genome multilocus sequence type (i.e., wgMLSType). However, existing data from conventional genotyping will be available in TB GIMS for jurisdictions’ reference in their TB prevention and control activities.
Genotyping-Based Cluster Detection
CDC identifies genotype-matched clusters, which can represent TB outbreaks, using geospatial analysis to identify unexpected clustering of TB cases within a defined time period. TB control programs can use this cluster detection information to help allocate and prioritize resources for investigation and intervention for specific cases that might be caused by recent transmission.
CDC’s primary cluster detection method is based on identifying higher than expected geospatial concentrations of a TB genotype in a specific county, compared with the national distribution of that genotype. This method calculates a log-likelihood ratio (LLR) statistic; clusters with higher LLRs represent greater geospatial concentrations than clusters with lower LLRs; higher LLRs might indicate recent transmission of TB. TB GIMS classifies LLRs into alert levels based on established cut points. Clusters are classified as *no alert* (LLRs 0–<4), *medium alert* (LLRs 4–<10), or *high alert* (≥10). The alert level and changes in alert levels (e.g., from no alert to medium- or high-level alerts) can help TB programs identify outbreaks by prioritizing TB genotype clusters for further investigation and possible intervention. CDC assesses characteristics of alerted clusters and communicates findings for priority clusters back to TB programs.
Genotyping Terminology
From 2009 to 2022 a genotype was defined in NTGS as a unique combination of spacer oligonucleotide typing (spoligotype) and 24-locus mycobacterial interspersed repetitive unit–variable number tandem repeat typing (MIRU–VNTR) results. Each unique combination of results was assigned a GENType designated as G followed by 5 digits, which were assigned sequentially to every genotype identified in the United States (e.g., G00162). Since 2018, genotype has included whole-genome sequencing-based methods that compare about 70% of the *Mycobacterium tuberculosis* genome. Nationally, isolates with ≥99.7% of their loci (i.e., genes) matching are considered clustered and they are assigned a wgMLSType designated by *MTBC* followed by 6-digits (e.g., MTBC000123). Otherwise, the isolate is designated as “MTBCunique.” Genotyping data from NTMSC should not be used for clinical decision making.
National TB Genotyping Surveillance Coverage in the United States
National TB genotyping surveillance coverage refers to the percentage of culture-positive TB cases with a genotyped *Mycobacterium tuberculosis* isolate. High levels of coverage in the United States can provide a better understanding of the molecular epidemiology of TB transmission within a specific geographic area and nationally. Additionally, because outbreak detection algorithms are based on identifying unexpected geospatial concentrations of cases whose isolates have the same genotype, high coverage levels help decrease the likelihood of false-negative alerts. Interpretation of genotyping data in areas where coverage is low should be performed with caution. The National Tuberculosis Indicators Project genotyping surveillance coverage target is 100% for 2022.5
Glossary
**alert level:** the alert level is determined by the log-likelihood ratio (LLR) statistic for a given county or county-equivalent defined genotype cluster. This is calculated by the Tuberculosis Genotyping Information Management System (TB GIMS) and is updated whenever a new case is added to a cluster. E-mail notifications are sent to TB GIMS users whenever an alert level for a given wgMLSType cluster changes from a no alert LLR (0–<4) to medium LLR (4–<10) or high LLR (≥10), or from a medium LLR to a high LLR alert level.
**cluster investigation:** a cluster investigation seeks to identify epidemiologic links among TB patients whose isolates have matching genotypes. It might include reviewing information from public health and medical records or interviewing case managers and outreach workers. It can also involve re-interview persons with TB.
**epidemiologic (epi) link:** an epidemiologic link indicates a relationship that two persons with TB share that might explain where, when, and how *Mycobacterium tuberculosis* was transmitted between them. Persons who name each other as contacts have an epidemiologic link. However, an epidemiologic link can also be a location where the two individuals spent time together or an activity that brought them together.
**genotype:** a genotype is the strain discrimination produced by genotyping techniques used for *Mycobacterium tuberculosis*, including spacer oligonucleotide typing (spoligotyping) and 24-locus mycobacterial interspersed repetitive unit–variable number tandem repeat typing analysis (MIRU-VNTR) and whole-genome sequencing. These designations were developed to facilitate communication of genotyping information among TB programs.
**genotype surveillance coverage:** genotyping surveillance coverage is defined as the percentage of culture-positive TB cases with a genotype result.
**genotyping cluster:** a cluster consisting of ≥2 cases in a jurisdiction during a specified period with *Mycobacterium tuberculosis* isolates that share matching genotypes. In the United States, all cases with matching wgMLSType are considered to be in a genotype cluster. The jurisdiction and period used to define clusters vary depending on the specific application. Within TB GIMS, a single county and a 3-year period are typically used to define a cluster.
**GENType:** a U.S. molecular surveillance designation for each unique combination of spoligotyping and 24-locus MIRU-VNTR analysis results. GENType is designated as a *G* followed by 5 digits, which were assigned sequentially to every genotype identified in the United States (e.g., G00017) from 2009 to July 2002.
**geospatial concentration:** a measure of how concentrated a genotype is in time and space. It indicates that recent transmission might have occurred, because patients with isolates having the same genotype and who reside closer to each other are more likely to have come in contact with each other. TB GIMS uses the log-likelihood ratio (LLR) to generate a statistical measure of geospatial concentration of a given TB genotype for purposes of cluster detection and alerting.
**linking:** the process of connecting genotyping results in TB GIMS with a corresponding TB case reported to NTSS. This process is essential for ensuring that demographic, risk factor, and geographic data can be viewed in TB GIMS for genotype clusters.
**log-likelihood ratio (LLR):** a measure of the geographic concentration of a specific genotype in a county, compared with the national distribution of that same genotype, throughout a 3-year period. A higher LLR indicates that the genotype has geospatial clustering within the county, which might indicate recent transmission of *Mycobacterium tuberculosis*.
**mycobacterial interspersed repetitive unit–variable number tandem repeat (MIRU-VTNR):** a polymerase chain reaction (PCR)-based assay used for genotyping. National Tuberculosis Genotyping Service (NTGS) performed 24-locus MIRU-VNTR analysis on every isolate submitted for genotyping until 2018; the National Tuberculosis Molecular Surveillance Center succeeded NTGS and continued MIRU-VNTR until July 2022. Before 2009, 12-locus MIRU-VNTR was performed. MIRU-VTNR distinguishes *Mycobacterium tuberculosis* strains by the difference in the number of copies of tandem repeats at specific regions, or loci, of the Mycobacterium tuberculosis genome.
***Mycobacterium bovis:*** a member of the Mycobacterium tuberculosis complex that is commonly associated with cattle and deer. In the United States, human cases of *M. bovis* TB typically have a foodborne origin (e.g., consumption of unpasteurized milk or dairy products). *M. bovis* is intrinsically resistant to pyrazinamide. Detection of TB caused by *M. bovis* can be performed through genotyping; however, this information should not be relied on for clinical decision making.
***Mycobacterium tuberculosis complex* (MTBC):** A group of closely related mycobacterial species that can cause latent TB infection (LTBI) and TB disease (i.e., *Mycobacterium tuberculosis, Mycobacterium bovis, Mycobacterium bovis bacillus Calmette-Guérin, Mycobacterium africanum, Mycobacterium orygis, Mycobacterium canetti, Mycobacterium caprae, Mycobacterium microti, Mycobacterium pinnipedii, Mycobacterium suricattae,* and *Mycobacterium mungi*). Among humans, most TB cases are caused by *M. tuberculosis*.
**National Tuberculosis Genotyping Service (NTGS):** NTGS provided TB genotyping services to local and state TB control programs until it was succeeded by the National Tuberculosis Molecular Surveillance Center in 2018. Since 2004, genotyping services have been provided at no cost to patients, health care providers, and health departments.
**National Tuberculosis Molecular Surveillance Center (NTMSC):** NTMSC was established in 2018 to perform whole-genome sequencing on ≥1 isolate from each newly diagnosed culture-positive TB case in the United States. NTMSC also provided MIRU-VNTR data on each isolate until July 2022.
**National Tuberculosis Surveillance System (NTSS):** NTSS is administered by the Centers for Disease Control and Prevention (CDC) and collects surveillance data through an electronic registry of TB cases. Data collected include demographic, clinical, and social risk factor variables that are reported to CDC by state and local health departments.
**PCRType:** a U.S. molecular surveillance designation for each unique combination of spoligotyping and 12-locus MIRU-VNTR. PCRType is designated as *PCR* followed by 5 digits, which were assigned sequentially to every genotype identified in the United States (e.g., PCR01974) from 2004 to July 2022.
**polymerase chain reaction (PCR):** a laboratory method that can rapidly amplify limited quantities of specific DNA, thereby enabling certain types of laboratory testing. Until July 2022, CDC’s genotyping services routinely used two PCR-based techniques, spoligotyping and MIRU-VNTR.
**recent transmission:** TB disease cases are designated as attributed to recent transmission if a plausible source case6 with the following five characteristics can be identified in the national surveillance data: the same *M. tuberculosis* genotype, an infectious form of TB disease, individual’s residential location ≤10 miles of the given case, individual’s age ≥10 years, and individual’s reported TB disease ≤2 years before the given case. Any given case with a plausible source case identified is included regardless of cluster size.
**reinfection:** disease caused by a second infection, often with a strain (genotype) of *Mycobacterium tuberculosis* different from the strain that caused the initial infection. (See also relapse.)
**relapse:** represents a clinical worsening of TB disease after treatment and a presumed period of improvement. It is caused by the same strain (genotype) of *Mycobacterium tuberculosis*. Genotyping the initial and the subsequent *Mycobacterium tuberculosis* isolates might help distinguish relapse from reinfection. (See also *reinfection*.)
**Report of a Verified Case of Tuberculosis (RVCT):** national case surveillance data regarding patients with TB disease, recorded on the standardized RVCT form and subsequently reported to the Centers for Disease Control and Prevention’s National Tuberculosis Surveillance System.
**spacer oligonucleotide typing (spoligotyping):** spoligotyping is based on spacer sequences located in the direct repeat region in the chromosomes of the *Mycobacterium tuberculosis* complex. The spoligotype uses an octal code to report results as a 15-digit number. Spoligotype can be derived from a polymerase chain reaction (PCR)-based assay or WGS. Spoligotyping was performed on every isolate submitted for genotyping until July 2022.
**Whole-Genome Sequencing (WGS):** Whole-Genome Sequencing generates usable DNA sequence data for approximately 90% of the *M. tuberculosis* genome.
**Whole-Genome Multilocus Sequence Typing (wgMLST):** A genotyping scheme that uses WGS data to compare sequences at 2,690 loci (about 70% of the MTBC genome). A locus is the location in the genome (i.e., one gene).
**wgMLSType:** a U.S. molecular surveillance designation for each whole-genome sequence analysis result from wgMLST. Isolates with wgMLST results that are clustered nationally, defined as matching at ≥99.7% of their loci, are assigned a wgMLSType designated by *MTBC* followed by 6-digits (e.g., MTBC000123). Otherwise, the isolate is designated as “MTBCunique.” wgMLSType is available since 2018 and it is the sole genotype designation used since July 2022.ReferencesCowan LS, Crawford JT. Genotype analysis of *Mycobacterium tuberculosis* isolates from a sentinel surveillance population. *Emerg Infect Dis.* 2002;8(11):1294-1302. Genotype analysis of Mycobacterium tuberculosis isolates from a sentinel surveillance population – PubMed (nih.gov)
Haddad MB, Diem MA, Cowan LS, et al. Tuberculosis genotyping in six low-incidence states, 2000–2003. *Am J Prev Med.* 2007;32(3):239-243. Tuberculosis genotyping in six low-incidence states, 2000-2003 – PubMed (nih.gov)
Ghosh S, Moonan PK, Cowan L, Grant J, Kammerer S, Navin TR. Tuberculosis Genotyping Information Management System: enhancing tuberculosis surveillance in the United States. *Infect Genet Evol.* 2012;12(4):782-788. Tuberculosis genotyping information management system: enhancing tuberculosis surveillance in the United States – PubMed (nih.gov)
Centers for Disease Control and Prevention. Tuberculosis Genotyping Information Management System. Atlanta, GA: U.S. Department of Health and Human Services, CDC; [undated]. https://www.cdc.gov/tb/programs/genotyping/tbgims/default.htm
Centers for Disease Control and Prevention. Monitoring tuberculosis programs—National Tuberculosis Indicator Project, United States, 2002–2008. *MMWR Morb Mortal Wkly Rep.* 2010;59(10):295-298. https://www.cdc.gov/mmwr/preview/mmwrhtml/mm5910a3.htm
France AM, Grant J, Kammerer JS, Navin TR. A field-validated approach using surveillance and genotyping data to estimate tuberculosis attributable to recent transmission in the United States. Am J Epidemiol. 2015;182(9):799-807. doi:10.1093/aje/kwv121
							
					
							Last Reviewed:  November 15, 2023						Source: 	Division of Tuberculosis Elimination, National Center for HIV, Viral Hepatitis, STD, and TB Prevention, Centers for Disease Control and Prevention
					Facebook
        Twitter
        LinkedIn
        Syndicate homeTuberculosisBasic TB Factsplus iconHow TB SpreadsLatent TB Infection and TB DiseaseSigns & SymptomsTB Risk FactorsExposure to TBTB PreventionVaccinesTB & HIV CoinfectionTB and DiabetesTB TermsPersonal StoriesTesting & Diagnosisplus iconWho Should be TestedTesting for TB InfectionTesting in BCG-Vaccinated PersonsTB Screening and Testing of Health Care PersonnelTesting During PregnancyDiagnosing latent TB infection and TB diseaseTreatmentplus iconDeciding When to Treat Latent TB InfectionTreatment Regimens for Latent TB Infection (LTBI)Treatment for TB DiseaseAdverse EventsTB Treatment of Persons Living with HIVTB Treatment and PregnancyTB Treatment for ChildrenFrequently Asked QuestionsDrug-Resistant TBResearchplus iconTB Epidemiologic Studies Consortiumplus iconResearch ProjectsPublicationsTB Trials Consortiumplus iconStudy DescriptionsBackgroundBehavioral & Social Science ResearchHealth Care Settingsplus iconTB Infection Control in Health Care SettingsResources for TB Screening and Testing of Health Care Personnelplus iconFrequently Asked QuestionsTB in Specific Populationsplus iconHealth DisparitiesAsian PersonsBlack or African American PersonsHispanic or Latino PersonsChildrenPregnancyCorrectional FacilitiesPeople Experiencing HomelessnessInternational TravelersLaboratory Informationplus iconDrug Susceptibility TestingFalse-Positive Investigation ToolkitInterim Laboratory Biosafety Guidance for XDR  tuberculosis strainsModel Performance Evaluation Program (MPEP)Rapid Molecular Testing to Detect Drug-Resistant TB in the USplus iconExecutive SummaryIntroductionBackground on Tests for Molecular Detection of DRGeneral Considerations and Principles for a Molecular DR Testing ServicePossible Scenarios and Scope of Testing for a Molecular DR Testing ServiceResearch NeedsGeneral Recommendations of the Expert PanelCommunication Plan for the ReportRecommendationsReferencesPanel Members and CDC ParticipantsAppendix 1Appendix 2Appendix 3The Uses of Nucleic Acid Amplification Tests for the Diagnosis of TBplus iconGeneral ConsiderationsGeneral Recommendations of the Expert PanelRecommendations to ACET, CDC, DTBEData & Statisticsplus iconTB Incidence in the United StatesReported TB in the US, 2022 Surveillance Reportplus iconNational DataReporting Area DataRisk FactorsDemographicsTB Treatment and Case OutcomesDrug-Resistant TBMolecular SurveillanceTuberculosis in the United States, 2022 (Slide Set)Archived Surveillance Reports and Slide Sets2021 State and City ReportArchived State and City ReportsProfessional Resources & Toolsplus iconTools for Healthcare ProvidersResources for TB Programsplus iconStrengthening Civil Surgeons’ Capacity to Improve LTBI Surveillance and Outcomes Among Status AdjustersNotice of Funding Opportunity (NOFO)Program EvaluationTB Centers of ExcellenceTB Elimination AllianceTB Genotypingplus iconConventional TB GenotypingWhole Genome SequencingTB GIMSAnalytic ToolsLatent Tuberculosis Infection ResourcesPublications & Productsplus iconPatient and Public MaterialsFact SheetsGuidelinesplus iconControl & EliminationDrug-Resistant TBInfection Control & PreventionLaboratory & GenotypingTB & HIVTB in Specific PopulationsTesting & DiagnosisTreatmentVaccines & ImmunizationsArchived TB GuidelinesGuides & Toolkitsplus iconAggregate ReportsCDC TB Surveillance TrainingCore CurriculumEffective TB Interviewing for Contact InvestigationEthnographic GuidesFalse-Positive Investigation ToolkitForging Partnerships to Eliminate TuberculosisGuide to Application of GenotypingLTBI: A Guide for Primary Health Care ProvidersMantoux Tuberculin Skin Testing ProductsReport of Verified Case of Tuberculosis (RVCT)Self-Study ModulesTB Contact Investigation Interviewing Skills CourseTB eDOT ToolkitUnderstanding the TB Cohort Review ProcessNewslettersplus iconTB Notes, No. 4, 2023TB Notes, No. 3, 2023TB Notes. No. 2, 2023TB Notes. No. 1, 2023TB Notes, No. 4, 2022TB Notes, No. 3, 2022TB Notes, No. 2, 2022TB Notes, No. 1, 2022TB Notes, No. 4, 2021TB Notes, No. 3, 2021TB Notes, No. 2, 2021TB Notes, No. 1, 2021Pamphlets, Brochures, Bookletsplus iconQuestions and AnswersPatient Education SeriesTuberculosis - Get the FactsTuberculosis - The Connection between TB and HIV12-Dose Regimen for Latent TB Infection-Patient Education BrochurePostersplus iconMantoux Tuberculin Skin Test Wall ChartWorld TB DayThink TBStop TBTake on TBReports & Articlesplus iconDTBE Authored Journal ArticlesTuberculosis Laboratory Aggregate ReportsSlide Setsplus iconIntroduction to TuberculosisEpidemiology of Tuberculosis Among Non-U.S.​–Born Persons in the United States, 1993–2016Self-Study Modules on Tuberculosis, 1-5 Slide SetsThe Tuberculosis (TB) in Correctional Settingsplus iconFacilitator GuideIntroduction to TB GenotypingEpidemiology of Tuberculosis in Correctional Facilities, United States, 1993-2017Prevention and Control of Tuberculosis in Correctional and Detention FacilitiesGuidelines for Preventing the Transmission of M. TB in Health care SettingsInvestigation of Contacts of Persons with Infectious TBEpidemiology of Pediatric Tuberculosis in the United StatesTargeted Tuberculosis Testing and Treatment of Latent Tuberculosis InfectionElectronic Tools & ResourcesWeb-Based Courses & Webinarsplus iconTB 101 for Health Care WorkersContent SyndicationInfographicsplus iconSocial Media GraphicsCustomizable Take on TB Infographic with InstructionsEventsWorld TB Dayplus iconU.S. TB ChampionsHistoryFeaturesplus iconTB Risk FactorsTreating Latent TB Infection with Short-Course RegimensWorld Tuberculosis (TB) Day 2021World Tuberculosis (TB) Day 2020Linksplus iconState TB Control OfficesAbout Usplus iconMission Statement and Activitiesplus iconDTBE Strategic PlanNational TB Program ObjectivesOrganization ChartAdvisory Groupsplus iconFederal TB Task Force To receive email updates about this page, enter your email address: Email Address			What's this?				Submit


About CDC
					Contact Us
					800-232-4636
 Facebook Twitter Instagram LinkedIn Youtube Pinterest Snapchat
 CONTACT CDC
				Contact Us
							Call 800-232-4636
							Email Us
			ABOUT CDC
				About CDC
							Jobs
							Funding
			POLICIES
				Accessibility
							External Links
							Privacy
							Policies
							No Fear Act
							FOIA
							OIG
							Nondiscrimination
							Vulnerability Disclosure Policy
			CONNECT WITH US
				Facebook
								Twitter
								Instagram
								LinkedIn
							Youtube
								Pinterest
								Snapchat
								Email
			LANGUAGES
				Español
							繁體中文
							Tiếng Việt
							한국어
							Tagalog
							Русский
							العربية
							Kreyòl Ayisyen
							Français
							Polski
							Português
							Italiano
							Deutsch
							日本語
							فارسی
							English


U.S. Department of Health & Human Services
			Accessibility
			External Links
			Privacy
			Policies
			No Fear Act
			FOIA
			Nondiscrimination
			OIG
			Vulnerability Disclosure Policy
			USA.gov


Exit Notification / Disclaimer Policy Close
 Links with this icon  indicate that you are leaving the CDC website. The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
				Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
				You will be subject to the destination website's privacy policy when you follow the link.
				CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website. Website Disclaimers
 Cancel Continue